Tom Carroll (@_tom_dot_com) profile picture

Co-Founder & CSO of Numen (@numenbio, YC S23) • Rice/Oxford Alum • Rhodes Scholar (Texas & Magdalen, 2016) • zipper club (Indiana & BAV, 2019)

San Francisco, CA
Joined July 2012
Photo by Tom Carroll (@_tom_dot_com)Photo by Tom Carroll (@_tom_dot_com)Photo by Tom Carroll (@_tom_dot_com)Photo by Tom Carroll (@_tom_dot_com)Photo by Tom Carroll (@_tom_dot_com)Photo by Tom Carroll (@_tom_dot_com)Photo by Tom Carroll (@_tom_dot_com)Photo by Tom Carroll (@_tom_dot_com)Photo by Tom Carroll (@_tom_dot_com)Photo by Tom Carroll (@_tom_dot_com)
Tom Carroll retweeted
Building @numenbio with @_tom_dot_com to engineer a future without cancer deaths. Find out more below in an interview with our partners at @TQVentures!
A cancer test that runs inside a cup. Taken at home, with results sent to your doctor in 30 minutes. Built in a San Francisco lab by a team that started in a shipping container. What it actually takes to build it: “If we spend ten, 20, 30, 40 years working on this, that’s okay. The outcome will be worth it.” @luca_springer, co-founder and CEO of @numenbio Timestamps: 00:00 Welcome to Numen 00:56 Why catch cancer early 01:24 The first lab was a shipping container 02:28 What the data unlocks next 03:23 National team MVP to founder 04:13 Why bladder cancer first 05:33 The candle prototype 06:25 Meet Atlas, a lab in a cup 06:55 NASA engineers under one roof 07:32 The Viennese café 08:08 Pipette pong 08:46 From the dungeon to Golden Gate Park 09:28 The only milestone that matters 09:59 40 years on one problem
5
6
202
Tom Carroll retweeted
A cancer test that runs inside a cup. Taken at home, with results sent to your doctor in 30 minutes. Built in a San Francisco lab by a team that started in a shipping container. What it actually takes to build it: “If we spend ten, 20, 30, 40 years working on this, that’s okay. The outcome will be worth it.” @luca_springer, co-founder and CEO of @numenbio Timestamps: 00:00 Welcome to Numen 00:56 Why catch cancer early 01:24 The first lab was a shipping container 02:28 What the data unlocks next 03:23 National team MVP to founder 04:13 Why bladder cancer first 05:33 The candle prototype 06:25 Meet Atlas, a lab in a cup 06:55 NASA engineers under one roof 07:32 The Viennese café 08:08 Pipette pong 08:46 From the dungeon to Golden Gate Park 09:28 The only milestone that matters 09:59 40 years on one problem
3
5
3
11
1,086
Tom Carroll retweeted
We’ve been building quietly at @numenbio for the past few years. Tomorrow we’re sharing more for the first time, in a conversation with Schuster at @TQVentures. Here’s a teaser; full interview tomorrow.
Inside the lab engineering a future without cancer deaths. Tomorrow: @numenbio with @luca_springer.
1
5
1
8
423
Tom Carroll retweeted
Operable setting (2026): sciencedirect.com/science/ar… Inoperable setting (2023): cell.com/cancer-cell/fulltex… In this new work, we also establish a 5-gene signature C-FISH correlated with TMC to allow estimation of this parameter when bulk RNA-seq is not available. Happy reading!
1
1
138
Tom Carroll retweeted
🚨 New paper out: Tumor monocyte content predicts immunochemotherapy outcomes for operable esophageal cancer. Similar to our previous work in inoperable setting, high TMC is associated w/ longer OS. May help identify EAC patients likely to respond to neoadjuvant ICI. Links below:
1
2
6
3,502
Tom Carroll retweeted
The reason mRNA can't cure more diseases? Delivery. We built NGX1 to deliver mRNA to any cell in the body using AI and multivalent physics.
8
24
6
69
8,284
Tom Carroll retweeted
Among cisplatin-eligible patients with muscle-invasive bladder cancer undergoing cystectomy, perioperative enfortumab vedotin–pembrolizumab led to significantly better event-free survival outcomes than cisplatin–gemcitabine. Full phase 3 KEYNOTE-B15/EV-304 trial results: nej.md/4wh8FB9 Editorial: A New Standard in Muscle-Invasive Bladder Cancer — The End of the Cisplatin Era? nej.md/4b67lZi
62
7
181
36,505
Tom Carroll retweeted
Truly monumental day for the #Ross community. Congratulations to trailblazers and colleagues @IHamamsy and @OuzounianMD for simultaneous publication of their incredible manuscripts reaffirming the magic of the Ross Procedure in @JACCJournals
12
47
3,709
Tom Carroll retweeted
🚨🚨🚨 RASOLUTE-302 Ph3 is POSITIVE "Daraxonrasib demonstrated a median OS of 13.2 months versus 6.7 months for chemotherapy, with a hazard ratio of 0.40 (p < 0.0001)".... WOW! AMAZING news for patients with #PancreaticCancer The RAS Revolution is ON!! ir.revmed.com/news-releases/…
20
231
38
731
258,764
For the second year in a row, Parafilm has been recognized with the Nobel Prize in Chemistry 2025! 🏅
15
476
76
2,817
129,849
Tom Carroll retweeted
This team 😂😂
20
248
9
3,104
158,735
8
69
2
939
46,885
Delighted to share the final version of Richard Zhou's study on how the CD163 scavenger receptor cleans up after toxic haemoglobin spills out from our blood cells. An amazing grabber mechanism! rdcu.be/ewPA2
11
2
39
2,243
Tom Carroll retweeted
Reminds me of one of the worst cases of scientific fraud ever: >cardiologist fakes data showing better outcomes for patients who were given beta blockers before surgery >Europe changes its medical guidelines based on this research >turns out beta blockers increase risk of death by 27% >might have killed up to 800,000 people
Great Q&A in Politico with James Heathers, who is leading the Medical Evidence Project to "find bad medical evidence before it kills people." nitter.cf/Meaningness/status/193…
67
741
59
5,859
428,200
Tom Carroll retweeted
Check out what we're working on at Olio Labs! 70% of patients taking GLP-1's (like Ozempic) are women, but they experience >2x side effect rates than men. What is driving this difference? We combine human EMR data, mouse & rat behavior, and scRNAseq to figure it out:
2
10
5
22
3,676
Tom Carroll retweeted
Today we report in @NatureMedicine the development of a base editing strategy for prion disease, currently a fatal and rapidly progressing neurogenerative condition with no effective treatment. @PrionAlliance @DevermanLab (1/13) drive.google.com/file/d/1DVp…
12
237
24
1,061
142,117
I’m excited to introduce Collate and announce our $30M seed round. We’re using AI to help solve one of the biggest problems for life sciences companies — the never-ending cycle of document creation and maintenance you need to do to stay compliant. While running my first company, I experienced the burden of documentation that life science companies face – from R&D to commercial readiness. Then at YC, I was lucky enough to witness the transformative, inevitable nature of software and AI. There's a unique opportunity here to bridge my two worlds. I'm thrilled to be building this alongside @nateps and @jigishjpatel. Thank you to our investors who have backed us with a $30M seed round: Satish Dharmaraj at Redpoint, @joshk at First Round and @saranormous at Conviction. And of course, YC. To YC and @garrytan - thank you for the invaluable gifts: a family of GPs I'll always count on, a deeper appreciation for software's potential, and most preciously, the privilege of supporting so many remarkable founders on their journeys. forbes.com/sites/alexkonrad/…
78
33
16
768
215,820
New #JITC article: Targeting the NLRP3 inflammasome abrogates cardiotoxicity of immune checkpoint blockers bit.ly/3Wclz3f
2
4
1,181
Scavenger receptor CD163 multimerises to allow uptake of diverse ligands biorxiv.org/cgi/content/shor… #biorxiv_biochem
1
134
Tom Carroll retweeted
What surviving the great SF Tsunami taught me about B2B sales 🧵
36
209
16
2,637
347,206